🇺🇸 FDA

Drug profile · INN

isosorbide dinitrate

ISORDIL SUBLINGUAL

FDA: approved TGA: approved
US status
approved
Patents linked
2
News articles
0

Quick answer

isosorbide dinitrate (ISORDIL SUBLINGUAL) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN isosorbide dinitrate
Brand ISORDIL SUBLINGUAL
Route ORAL
Formulation TABLET, EXTENDED RELEASE
Originator Lacuna Pharma Pty Ltd

Related patents

Search patents →

  1. US 10213389

    Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9463166

    Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is isosorbide dinitrate?

isosorbide dinitrate (ISORDIL SUBLINGUAL) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for isosorbide dinitrate?

ISORDIL SUBLINGUAL is a marketed brand name for isosorbide dinitrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of isosorbide dinitrate?

isosorbide dinitrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.